Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommonwealth Care Alliance Drug PA Update | OpenPa…
    Ask Trek AI about this page
    Modifiedcommonwealth_care_alliancePolicy N/A

    Pharmacy Drug Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all commonwealth_care_alliance policy alerts

    Know when commonwealth_care_alliance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs prior authorization requirements for a broad list of prescription, specialty, infusion, biologic, oncology, and vaccine products. It specifies covered indications, required clinical information, prerequisite therapy, age and prescriber restrictions, and authorization durations for providers.

    Policy Summary
    PayerCommonwealth Care Alliance
    PolicyPharmacy Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the requested indication and drug-specific clinical documentation for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Plan YearMost common coverage duration
    65+High-risk medication age threshold
    150 cells/mcLDupixent asthma baseline eosinophil threshold
    11 micromol/LAlpha1-proteinase inhibitor threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Drug-Specific Coverage Criteria

    Drug-Level Prior Authorization Criteria

    Drug-specific prior authorization criteria are applied to the requested product, indication, diagnosis, biomarker, age, prior therapy, prescriber qualifications, and coverage duration as stated below.

    Androgen receptor-directed therapy

    • For abiraterone, abiraterone acetate, Abirtera, Akeega, Erleada, Nubeqa, and related androgen receptor-directed therapy, the drug must be used with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.
    • For recurrent androgen-receptor-positive salivary gland tumors, disease must be recurrent, metastatic, or unresectable and androgen-receptor positive.

    Oncology and biomarker-directed therapy

    • Coverage requires the applicable tumor diagnosis, disease stage or recurrence status, and documented biomarker or mutation specified for the requested product, including ALK, BRAF, EGFR, FGFR, HER2/ERBB2, KRAS G12C, RET, BRCA, PDGFRA, PDGFRB, FLT3, FGFR1, IDH2, KIT, PIK3CA, or NTRK alterations when applicable.
    • For products requiring combination therapy, the requested drug must be used with the specified partner, such as binimetinib, cetuximab, panitumumab, encorafenib, dabrafenib, trastuzumab, pertuzumab, tucatinib, lapatinib, fulvestrant, endocrine therapy, or a GnRH analog.

    Alosetron

    • For severe diarrhea-predominant irritable bowel syndrome, the patient is biologically female or identifies as female, has chronic IBS symptoms for at least 6 months, gastrointestinal tract abnormalities have been ruled out, and there was an inadequate response to one conventional therapy such as an antispasmodic, antidepressant, or antidiarrheal.

    Benlysta

    • For systemic lupus erythematosus, the patient is receiving standard therapy or has an intolerance or contraindication to standard therapy; for initial therapy, diagnosis is confirmed by relevant SLE autoantibodies.
    • For lupus nephritis, the patient is receiving standard lupus-nephritis therapy or has an intolerance or contraindication; for initial therapy, diagnosis is confirmed by kidney biopsy or relevant SLE autoantibodies.
    • For new therapy in severe active central nervous system lupus, the patient has severe active CNS disease.
    • Age requirement: 5 years or older.

    Berinert and Icatibant

    • For acute hereditary angioedema attacks, HAE with C1-inhibitor deficiency or dysfunction must be confirmed by laboratory testing.
    • For HAE with normal C1 inhibitor, laboratory confirmation plus an eligible F12, angiopoietin-1, plasminogen, KNG1, HS3ST6, or MYOF mutation is required, or there must be a family history of angioedema refractory to high-dose antihistamine therapy for at least 1 month.
    • Berinert must be prescribed by or in consultation with an immunologist, allergist, or rheumatologist. Icatibant requires age 18 years or older and the same specialist qualification.

    Bosentan and Bosulif

    • For bosentan and pulmonary arterial hypertension, PAH must be confirmed by right-heart catheterization; for new starts, mean pulmonary arterial pressure is greater than 20 mmHg, pulmonary capillary wedge pressure is 15 mmHg or less, and pulmonary vascular resistance is greater than 2 Wood units. Adults must also have inadequate response, intolerance, or contraindication to ambrisentan.
    • For Bosulif, CML or Ph-positive ALL requires Philadelphia chromosome or BCR-ABL confirmation. CML requires resistance or intolerance to imatinib, dasatinib, or nilotinib; resistant disease must be negative for T315I, G250E, V299L, and F317L mutations. Ph-positive ALL with prior TKI resistance must have the same mutation exclusions.

    Braftovi

    • Colorectal or appendiceal cancer: BRAF V600E-positive advanced or metastatic or unresectable metachronous disease, used with cetuximab or panitumumab.
    • Melanoma: BRAF V600 activating mutation-positive disease, used alone or with binimetinib, for unresectable, limited resectable, metastatic, adjuvant, or neoadjuvant treatment.
    • NSCLC: BRAF V600E-positive advanced, recurrent, or metastatic disease, used with binimetinib.

    Buprenorphine patch and Fentanyl patch

    • The drug is for cancer, sickle-cell, terminal, or palliative-care pain, or for severe persistent pain requiring extended daily opioid therapy in a patient already taking opioids.
    • The patient can safely take the requested dose based on opioid history, has been evaluated and will be monitored for opioid use disorder, and has received an extended-release opioid for at least 30 days or an immediate-release opioid for at least 1 week.
    • Prescribing is limited to clinicians knowledgeable in potent opioids for chronic pain. Prior opioid therapy is required.

    Bysanti schizophrenia and bipolar disorder

    • Schizophrenia: inadequate response, intolerance, or contraindication to one listed generic antipsychotic and one listed brand antipsychotic, including Caplyta, Cobenfy, Lybalvi, Rexulti, Secuado, or Vraylar.
    • Bipolar I manic or mixed episodes: inadequate response, intolerance, or contraindication to one listed generic antipsychotic and one listed brand product, Lybalvi or Vraylar.

    Calquence; Cometriq and Copiktra

    • Calquence for marginal-zone lymphoma requires relapsed, refractory, or progressive disease; other covered hematologic indications must meet the applicable FDA-approved diagnosis.
    • Cometriq for NSCLC requires RET rearrangement-positive disease.
    • Copiktra for CLL/SLL, breast-implant-associated ALCL, or peripheral T-cell lymphoma requires relapsed or refractory disease; hepatosplenic T-cell lymphoma requires refractory disease.

    Cayston

    • For respiratory symptoms in cystic fibrosis, Pseudomonas aeruginosa is present in airway culture or there is a documented history of Pseudomonas infection or colonization.

    Clorazepate and diazepam

    • For patients 65 years or older, the prescriber acknowledges that benefit outweighs risk and, when two or more additional CNS-active medicines are used, confirms that polypharmacy is medically necessary because of fall risk.
    • For anxiety disorders, the drug is used with an SSRI or SNRI until effective, or the patient has failed, not tolerated, or has a contraindication to at least two SSRIs or SNRIs.
    • Clorazepate applies to therapy exceeding cumulative 5 days per year; diazepam criteria apply to the specified short-term, muscle-spasm, anxiety-disorder, and other-diagnosis durations.

    Cystinosis ocular therapy and nephropathic cystinosis

    • For Cystadrops or Cystaran, cystinosis is confirmed by increased leukocyte cystine, genetic testing, or corneal cystine crystals on slit-lamp examination, and corneal crystal accumulation is present.
    • For Cystagon, nephropathic cystinosis is confirmed by increased leukocyte cystine, genetic testing, or corneal cystine crystals on slit-lamp examination.

    Daurismo and Deferasirox

    • Daurismo for AML is used with cytarabine in a patient age 75 or older or with comorbidities precluding intensive chemotherapy, for induction or post-induction/consolidation after response to the same regimen.
    • Deferasirox for transfusional chronic iron overload requires pretreatment serum ferritin greater than 1000 mcg/L.

    Dexmethylphenidate

    • The patient has ADHD or ADD, or narcolepsy confirmed by sleep study, or the drug is being used for cancer-related fatigue after other causes have been ruled out.

    Dupixent

    • Atopic dermatitis: moderate-to-severe disease with inadequate response to a topical corticosteroid or calcineurin inhibitor, or those therapies are inadvisable.
    • Asthma: inadequate control despite the required inhaled corticosteroid and controller therapy, unless contraindicated or not tolerated; eosinophilic asthma requires baseline eosinophils at least 150 cells/microliter.
    • CRSwNP requires add-on maintenance treatment and, for adults, inadequate response to Xhance. EoE requires biopsy with at least 15 eosinophils per high-power field, symptoms, weight at least 15 kg, and failure or contraindication of topical corticosteroid.
    • COPD requires standard triple therapy or LAMA/LABA when inhaled corticosteroid is contraindicated, plus absolute eosinophils at least 300 cells/microliter.
    • CSU requires symptoms for at least 6 weeks despite H1 antihistamine therapy and evaluation for alternative causes. BP requires confirmatory immunofluorescence or serology and failure or contraindication of topical or systemic corticosteroid. AFRS requires prior sinonasal surgery and the specified fungal hypersensitivity, polyp, CT, and eosinophilic mucin findings.

    Etanercept and Eucrisa

    • Etanercept for rheumatoid arthritis requires inadequate response, intolerance, or contraindication to methotrexate or a prior biologic or targeted synthetic DMARD; axial spondyloarthritis requires NSAID failure, intolerance, or contraindication; psoriasis requires qualifying body-area or BSA severity and failure, intolerance, or contraindication to phototherapy or methotrexate, cyclosporine, or acitretin; hidradenitis suppurativa requires severe refractory disease.
    • Eucrisa for mild-to-moderate atopic dermatitis requires failure, intolerance, or contraindication to a topical calcineurin inhibitor on sensitive areas or a medium/high-potency topical corticosteroid or calcineurin inhibitor on nonsensitive areas; minimum age is 3 months.

    Everolimus disease criteria

    • Breast cancer must be recurrent, unresectable, advanced, or metastatic HR-positive/HER2-negative disease, used with exemestane, fulvestrant, or tamoxifen as subsequent therapy.
    • Renal cell carcinoma must be relapsed, advanced, or stage IV. GIST must be residual, recurrent, unresectable, or metastatic/tumor rupture and progressed after at least two FDA-approved therapies.
    • SEGA is covered when used as adjuvant treatment. ECD, Rosai-Dorfman disease, and LCH require a PIK3CA mutation.

    FOTIVDA and FRUZAQLA

    • FOTIVDA for renal cell carcinoma requires advanced, relapsed, refractory, or stage IV disease and at least two prior systemic therapies.
    • FRUZAQLA for colorectal or appendiceal adenocarcinoma requires advanced or metastatic disease, single-agent use, and second-line or subsequent therapy.

    Gavreto and Gilotrif

    • Gavreto for NSCLC requires recurrent, advanced, or metastatic RET fusion- or RET rearrangement-positive disease; NSCLC use is for adults.
    • Gilotrif for EGFR-positive NSCLC requires recurrent, advanced, or metastatic disease and intolerance or contraindication to erlotinib, gefitinib, or osimertinib, or metastatic squamous NSCLC progressed after platinum chemotherapy.

    High-risk medications and amitriptyline

    • For high-risk medications in patients 65 years or older, the prescriber must acknowledge that benefit outweighs risk; additional CNS-active or anticholinergic medication requires a medically necessary polypharmacy determination.
    • Amitriptyline for extrapyramidal symptoms requires no trial of amantadine because of contraindication, or inadequate response or intolerance after an amantadine trial.
    • Amitriptyline for Parkinson disease requires failure or intolerance of two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole.
    • Amitriptyline for depression requires trials and inadequate response or intolerance to two of an SSRI, SNRI, bupropion, mirtazapine, or trazodone.
    • Amitriptyline for anxiety requires trials and inadequate response or intolerance to two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine ER, or acute anxiety when two alternatives were not tried.

    Humira and oncology criteria for Hyrnuo and Ibrance

    • Humira disease-specific criteria mirror the biologic step requirements for rheumatoid arthritis, axial spondyloarthritis, psoriasis, and noninfectious uveitis: failure, intolerance, or contraindication to the applicable methotrexate, NSAID, corticosteroid, biologic, or targeted synthetic DMARD therapy.
    • Hyrnuo for NSCLC requires HER2/ERBB2 mutation-positive recurrent, advanced, or metastatic disease and subsequent therapy.
    • Ibrance for breast cancer requires advanced, recurrent, or metastatic HR-positive disease; HER2-negative disease requires specified Kisqali or Verzenio intolerance/contraindication, or endocrine-resistant PIK3CA-mutated disease with inavolisib and fulvestrant. HER2-positive disease requires trastuzumab and endocrine therapy.

    Iclusig, Idhifa, and imatinib products

    • Iclusig for CML requires accelerated or blast phase without another indicated kinase inhibitor, chronic phase resistant or intolerant to at least two kinase inhibitors including imatinib, T315I mutation, or resistance without an identifiable BCR-ABL1 mutation. ALL requires Philadelphia chromosome or BCR-ABL confirmation. GIST requires residual, unresectable, recurrent, or metastatic/tumor-rupture disease progressed after at least two FDA-approved therapies.
    • Idhifa for IDH2-mutated AML covers newly diagnosed patients not candidates for or declining intensive induction, post-induction therapy after response, relapsed or refractory disease, or consolidation therapy.
    • Imatinib products require disease-specific confirmation and sequencing. CML or Ph-positive ALL requires Philadelphia chromosome or BCR-ABL confirmation; CML generally requires no prior TKI failure except intolerance. Imkeldi additionally requires inability to use imatinib tablets.

    Inbrija, Increlex, Inlyta, insulin supplies, and IR-before-ER opioids

    • Inbrija initial therapy for Parkinson off episodes requires concurrent oral carbidopa/levodopa and no asthma, COPD, or other chronic lung disease; continuation requires improvement.
    • Increlex requires severe primary IGF-1 deficiency or GH-gene deletion with height and IGF-1 at least 3 SD below mean and normal or elevated provocative GH, with improvement required for continuation; minimum age is 2 years and endocrinology consultation is required.
    • Inlyta for renal cell carcinoma requires advanced, relapsed, or stage IV disease.
    • Insulin supplies must be used with insulin.
    • Immediate-release opioid therapy must be tried or deemed unsuitable before extended-release hydrocodone, methadone, morphine, or OxyContin; opioid-risk and safety requirements apply.

    Jideytro and BTK sequencing

    • For Jideytro, FDA-approved use is subject to the applicable diagnosis and requires prior treatment with a covalent BTK inhibitor such as Calquence or Brukinsa for CLL/SLL, mantle-cell lymphoma, or marginal-zone lymphoma when specified.

    Kanjinti and trastuzumab products

    • Kanjinti, Herceptin, Herceptin Hylecta, Herzuma, Ogivri, and Ontruzant cover the listed HER2-positive breast, gastric, esophageal, uterine, salivary, hepatobiliary, and colorectal indications when the required HER2, RAS, and BRAF findings and combination therapy are documented.
    • The requested product must address an intolerable adverse event to Trazimera not attributed to trastuzumab's active ingredient. Colorectal disease requires HER2 amplification and RAS/BRAF wild-type status plus specified HER2 combination therapy or metachronous metastases. Hepatobiliary disease requires HER2 positivity with pertuzumab or tucatinib; endometrial disease requires paclitaxel followed by maintenance monotherapy.
    • Part D coverage is denied when the product is covered under Part A or Part B as prescribed, dispensed, or administered.

    Ketoconazole

    • Oral ketoconazole is excluded in acute or chronic liver disease and with contraindicated interacting drugs. The prescriber must document that benefits outweigh risks. Systemic fungal infection must be blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis; Cushing syndrome requires inability to tolerate surgery or noncurative surgery.

    Koselugo; Krazati and Lumakras

    • Koselugo requires the applicable NF1-associated inoperable symptomatic plexiform neurofibroma or eligible BRAF fusion/V600E tumor diagnosis.
    • Krazati and Lumakras for NSCLC require recurrent, advanced, or metastatic KRAS G12C-positive disease. Other colorectal, pancreatic, ampullary, appendiceal, or biliary indications require the corresponding KRAS G12C-positive diagnosis and stage.

    Leuprolide and Lupron Depot-Ped

    • For central precocious puberty, diagnosis requires a pubertal response to GnRH agonist testing or pubertal third-generation LH, supportive bone-age assessment, and secondary sexual characteristics before age 8 in females or before age 9 in males. CPP treatment is limited to females younger than 12 and males younger than 13.
    • Leuprolide may also be covered for recurrent androgen-receptor-positive salivary gland tumors and for specified breast, ovarian, fallopian-tube, peritoneal, endometriosis, or fibroid indications; Lupron Depot-Ped is for CPP.

    Lynparza and Lytgobi

    • Lynparza for recurrent or metastatic breast cancer requires germline BRCA mutation; ovarian/fallopian-tube/primary-peritoneal maintenance requires complete or partial response to chemotherapy; prostate cancer requires BRCA mutation and the specified androgen-receptor therapy or abiraterone combination; uterine leiomyosarcoma requires prior therapy and BRCA-altered disease.
    • Lytgobi for cholangiocarcinoma requires unresectable locally advanced or metastatic disease, subsequent therapy, and FGFR2 fusion or rearrangement.

    Mekinist and Mektovi

    • Mekinist melanoma and solid-tumor criteria require BRAF mutation and the specified single-agent or dabrafenib combination; thyroid carcinoma requires BRAF V600E, lack of RAI suitability, and dabrafenib combination.
    • Mektovi melanoma requires BRAF V600 activating mutation and encorafenib combination for unresectable, limited resectable, metastatic, adjuvant, or neoadjuvant disease. NSCLC requires BRAF V600E, advanced/recurrent/metastatic disease, and encorafenib combination.

    Mepron through Nuedexta

    • Mepron requires intolerance or contraindication to TMP-SMX for PCP treatment or prophylaxis and immunocompromise for prophylaxis; babesiosis requires concurrent azithromycin.
    • Nitisinone requires hereditary tyrosinemia type 1 confirmed by succinylacetone or other biochemical testing, genetic testing, or enzyme assay.
    • Northera initial therapy requires the specified orthostatic blood-pressure decrease within 3 minutes of standing or tilt testing; continuation requires sustained symptom reduction and an eligible neurogenic diagnosis.
    • Nuplazid requires Parkinson disease diagnosed before psychotic symptoms for Parkinson disease psychosis.
    • Nurtec acute migraine treatment requires failure, intolerance, or contraindication to at least one triptan; preventive therapy prohibits concurrent CGRP-receptor antagonist and requires reduced migraine days for continuation.

    Ojjaara, Pomalyst, Procrit, Pyzchiva, Rubraca, and Rydapt

    • Ojjaara requires intermediate- or high-risk primary or secondary myelofibrosis, hemoglobin below 10 g/dL or transfusion-dependent anemia, and failure, intolerance, or contraindication to Jakafi, unless hemoglobin is below 8 g/dL.
    • Pomalyst for multiple myeloma requires at least two prior therapies including an immunomodulatory agent and a proteasome inhibitor; additional listed lymphoma and amyloidosis indications must meet the disease-specific criteria.
    • Procrit initial therapy requires adequate iron stores when applicable, pretreatment hemoglobin below 10 g/dL except specified uses, and serum erythropoietin 500 IU/L or less for MDS. Reauthorization requires at least 12 weeks of therapy, response, current hemoglobin below 12 g/dL, and adequate iron stores when applicable. Part A/B coordination exclusions apply.
    • Pyzchiva for moderate-to-severe plaque psoriasis requires qualifying crucial-area involvement, at least 10% BSA, or at least 3% BSA with failure, intolerance, or contraindication to phototherapy or methotrexate, cyclosporine, or acitretin.
    • Rubraca for metastatic castration-resistant prostate cancer requires BRCA mutation, prior androgen-receptor therapy, prior taxane or chemotherapy-ineligibility, and GnRH analog or orchiectomy. Ovarian maintenance requires BRCA-mutated disease and response to primary or platinum chemotherapy; uterine leiomyosarcoma requires subsequent therapy and BRCA-altered disease; pancreatic cancer requires metastatic BRCA or PALB2-mutated disease.

    Coverage is excluded when the request is for an unlisted or unsupported indication, when required diagnostic, biomarker, laboratory, age, or disease-severity documentation is absent, or when a prohibited combination or contraindicated therapy is used.

    Coverage under Part D is denied when the medication is available under Part A or Part B as prescribed, dispensed, or administered. This applies particularly to trastuzumab products, Procrit, IVIG, and other products with site-of-care or benefit-category restrictions.

    Products with required biomarkers must not be substituted for a different mutation or disease subtype. Combination requirements, prior-line requirements, and specified sequencing requirements are product-specific and must be documented.

    Initial Therapy Criteria

    Initial approval requires the applicable diagnosis, disease severity, laboratory or biomarker confirmation, age requirement, and prerequisite therapy listed for the product.

    Initial therapy

    • Diagnosis is confirmed using the required pathology, laboratory, genetic, biomarker, imaging, or physiologic testing for the requested indication.
    • Disease meets the required severity, stage, recurrence, refractoriness, or treatment-failure threshold.
    • Required prerequisite therapy has been tried, is contraindicated, or is clinically inadvisable, as applicable.
    • The patient meets the product-specific age restriction and the request is prescribed by or in consultation with the required specialist when specified.

    Examples of required confirmation

    Continuation and Reauthorization Criteria

    Continuation or reauthorization requires evidence of treatment response, clinical benefit, laboratory response, or completion of the required prior-treatment duration.

    Continuation therapy

    • The patient achieved or maintained a positive clinical response or clinically meaningful benefit from the requested drug.
    • Disease-specific objective measures improved or remained within the permitted range, such as migraine days, cluster-headache attacks, platelet count, IGF-1, hemoglobin, eosinophil count, parenteral-support requirement, wound status, or pulmonary symptoms.
    • The patient continues to meet the diagnosis, safety, age, combination-therapy, and monitoring requirements and has not developed an exclusion or contraindication.

    Product-specific continuation examples

    • Dupixent, Inbrija, Increlex, Nurtec, Northera, and Octreotide require documented improvement or response using the applicable symptom, laboratory, or functional measure.
    Step-therapy or sequencing requirementAffected products and required sequence
    Androgen receptor-directed therapyUse with a GnRH analog or after bilateral orchiectomy for abiraterone, Akeega, Erleada, Nubeqa, and related products; Rubraca and Lynparza prostate indications require the applicable prior androgen-receptor therapy.
    Biologic and immunologic therapyEtanercept and Humira require the applicable methotrexate, NSAID, corticosteroid, biologic, or targeted synthetic DMARD trial. Dupixent and Eucrisa require the applicable topical, inhaled, systemic, or antihistamine therapy trial unless contraindicated.
    Oncology kinase and targeted therapyBosulif, Calquence, Iclusig, Imatinib, Jideytro, Krazati, Lumakras, Lytgobi, Mektovi, Rubraca, and related products require product-specific prior kinase inhibitor, endocrine, chemotherapy, biomarker, or subsequent-line sequencing.
    Opioid and high-risk medication safeguardsBuprenorphine and fentanyl patches require prior opioid exposure and monitoring; IR-before-ER opioid criteria require immediate-release therapy before extended-release therapy. High-risk medications and amitriptyline require prescriber risk acknowledgment and medically necessary polypharmacy documentation.
    Hematology and supportive careProcrit requires the specified hemoglobin, iron, erythropoietin-level, and response criteria; Pomalyst requires prior immunomodulatory and proteasome-inhibitor therapy; FOTIVDA requires at least two prior systemic therapies; Pyzchiva requires prior phototherapy or systemic psoriasis therapy unless contraindicated.

    Authorization Durations and Quantity Limits

    Drug-Specific Quantity Limits and Authorization Durations
    FlucytosineCoverage duration: peritonitis 1 month; Candida 6 weeks; cryptococcosis 6 months.
    High-risk medicationsFor patients 65 years or older: prior authorization generally applies after the specified cumulative annual threshold; prescriber must document that benefits outweigh risks and address interacting anticholinergic or CNS medications. Amitriptyline, cyproheptadine, meclizine, promethazine and related HRM criteria include a 3-month duration; thresholds are generally greater than 30 or 90 cumulative days per year, depending on the drug.
    Ivermectin tabletsCoverage duration: 1 month. The drug must not be prescribed for prevention or treatment of COVID-19.
    NortheraCoverage duration: 3 months. Document neurogenic orthostatic hypotension, qualifying blood-pressure findings for initial therapy, and sustained symptom reduction for continuation.
    NuedextaInitial coverage: 4 months; continuation: plan year. Document pseudobulbar affect caused by neurologic disease or injury, characteristic involuntary laughing or crying episodes, and clinical improvement for renewal.
    NurtecPreventive initial coverage: 3 months; other indications: plan year. Acute migraine requires inadequate response, intolerance, or contraindication to at least one triptan; preventive therapy may not be combined with another CGRP antagonist and continuation requires reduced migraine days after at least 3 months.
    PosaconazoleCoverage duration: 6 months. Oral administration is required; prophylaxis of invasive Aspergillus or Candida requires weight greater than 40 kg and age 2 years or older.
    PrevymisCoverage duration: 7 months. CMV prophylaxis requires CMV-seropositive status and allogeneic HSCT, or CMV-seronegative high-risk kidney-transplant status; minimum ages are 6 months for HSCT and 12 years for kidney transplant.
    ProcritDocument indication-specific initial and renewal criteria, including iron stores, hemoglobin, serum erythropoietin for MDS, at least 12 weeks of prior therapy, response, and current hemoglobin for reauthorization.
    Quinine sulfateCoverage duration: 1 month. For babesiosis, use must be in combination with clindamycin.
    QuliptaInitial preventive coverage: 3 months; continuation: plan year. Do not combine with another CGRP antagonist; continuation requires at least 3 months of treatment and fewer migraine days from baseline.
    SantylCoverage duration: 3 months. For continuation of debridement of chronic dermal ulcers or severely burned areas, document wound reassessment and that granulation tissue is not well established.
    Prior Authorization

    Prior Authorization, Prerequisite Therapy, Documentation, and Denial Rules

    Prior authorization is required for the listed drugs, supplies, and specialty products. Approval depends on the indication-specific clinical criteria, prerequisite therapy, exclusions, documentation, age, specialist, and duration requirements below. Submit sufficient clinical records to establish medical necessity and the requested duration.

    • Medicare Part B or Part D determination: For applicable drugs and supplies, coverage may depend on where and how the product is administered or dispensed. Submit the drug, use, and site-of-care information; Part D is denied when Part A or Part B coverage applies. This applies to applicable medical-benefit products, including certain oncology and IVIG products.
    • Drug-specific prior authorization: Obtain PA for the requested product and indication and comply with the drug-specific authorization duration. A general PA does not replace indication-specific criteria.
    • Prior authorization and prerequisite therapy: When prerequisite therapy is required, document inadequate response, intolerance, contraindication, or completion of the required sequence. Required examples include methotrexate or prior biologic/targeted DMARD therapy for Hadlima; two qualifying agents for KINERET; prior TNF or systemic therapy for Rinvoq; prior therapy for Lonsurf, Lorbrena, Lynparza, Nexavar, Qinlock, Rubraca, Jakafi, Megestrol, and other oncology products; and topical corticosteroid or calcineurin-inhibitor therapy for Dupixent.
    • Older-adult safety restrictions: For high-risk medications, including clorazepate and HRM products, document that benefit outweighs risk. Review anticholinergic burden, falls, cognition, and concurrent CNS medications; justify polypharmacy and monitor when multiple CNS-active or anticholinergic drugs are medically necessary.

    Clinical Thresholds and Coding Values

    Clinical reference thresholds
    Pulmonary hypertensionMean pulmonary arterial pressure >20 mmHg; pulmonary capillary wedge pressure ≤15 mmHg; pulmonary vascular resistance >2 Wood units
    Alpha1-proteinase inhibitor deficiency<11 micromol/L; equivalent to 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry
    Platelet criteriaITP initial: <30,000/mcL, or 30,000-50,000/mcL with symptomatic bleeding or bleeding risk; Doptelet chronic liver disease: <50,000/mcL before a scheduled procedure; systemic mastocytosis: ≥50,000/mcL
    Psoriasis severityAt least 10% BSA for severe psoriasis biologic first-line therapy, or at least 3% BSA with qualifying prior therapy failure, intolerance, or contraindication
    Eosinophilic diseaseDupixent asthma: ≥150 cells/microliter; Dupixent COPD: at least 300 cells/microliter; Dupixent EoE: ≥15 intraepithelial esophageal eosinophils per high power field; Fasenra HES: at least 1000 cells/microliter
    Growth and weight criteriaPediatric GHD: peak GH below 10 ng/mL on 2 failed stimulation tests; growth height more than 2 standard deviations below mean; SGA birth weight less than 2500 g at gestational age greater than 37 weeks; Dupixent EoE weight at least 15 kg
    Anemia, immunoglobulin, glucose, and fibrosis criteriaLupron fibroid anemia: hematocrit ≤30% and/or hemoglobin ≤10 g/dL; Procrit pretreatment hemoglobin <10 g/dL and reauthorization hemoglobin <12 g/dL; IVIG IgG: <500 mg/dL for B-cell CLL or <400 mg/dL for BMT/HSCT and pediatric HIV; Omnipod: glucose testing at least 4 times daily or continuous glucose monitoring; Rezdiffra: F2-F3 fibrosis

    Prior Authorization and Documentation Requirements

    Documentation Required

    Include complete clinical support with every request

    Submit the requested indication and all applicable clinical information with each prior authorization request. Depending on the product, documentation may include diagnosis and disease stage or severity, biomarker or mutation results, diagnostic confirmation, laboratory values, treatment history, response or intolerance, required combination therapy, age, treatment setting, and specialist involvement.

    • Document inadequate response, intolerance, or contraindication to required generic, brand, topical, disease-specific, or combination therapies when applicable.
    • Provide required laboratory and diagnostic evidence, such as right-heart catheterization and pretreatment hemodynamics for pulmonary hypertension, biomarker or mutation testing for oncology requests, and applicable platelet, eosinophil, hemoglobin, IgG, ferritin, or IGF-1 values.
    • Include treatment response for continuation or reauthorization requests when required.
    • Use the required specialist or consultation pathway for products with prescriber restrictions.
    Denial Risk

    Prevent avoidable denial conditions

    Requests may be denied when required documentation, prerequisite therapy, indication criteria, laboratory values, age or specialist requirements, combination therapy, or treatment setting are not satisfied. Coverage is also denied for prohibited combinations, excluded indications, and products payable under Medicare Part A or Part B rather than Part D.

    • Do not submit DHE nasal or ergotamine with potent CYP3A4 inhibitors.
    • Do not use Alyftrek, KALYDECO, or Orkambi with another CFTR potentiating agent.
    • Document required prior therapies, such as prior kinase inhibitors, approved GIST therapies, oral carbidopa/levodopa for initial Inbrija, or inability to use imatinib tablets for Imkeldi.
    • Check age and prescriber restrictions, including the minimum age for icatibant and Increlex and required specialist involvement.
    • Part D coverage will be denied when Part A or Part B coverage applies.
    Documentation Required

    Provide targeted diagnostic and treatment evidence

    For targeted requests, submit objective confirmation of the diagnosis and the specific clinical features required for the requested drug. Include disease stage or severity, biomarker or genetic findings, relevant laboratory values, prior treatment and response, planned regimen, monitoring or continuation response, transplant status, and required specialist consultation when applicable.

    • Pulmonary hypertension: right-heart catheterization and, for new starts, mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure no greater than 15 mmHg, and pulmonary vascular resistance greater than 2 Wood units when applicable.
    • Oncology: provide required mutation or biomarker results, disease setting or stage, prior treatment history, combination regimen, and treatment line.
    • Inherited and rare disease requests: provide the specified biochemical, enzyme, genetic, biopsy, or laboratory confirmation.
    • Continuation or renewal: document clinical benefit, response, current laboratory values, or wound reassessment as required.

    Site of Care and Prescriber Requirements

    Billing Rule

    Confirm the benefit and specialist pathway before submission

    The drug’s use and treatment setting determine whether coverage falls under Medicare Part B or Part D. Submit the site-of-care, administration, prescribing, and dispensing information needed to make the determination, and verify required specialist prescribing or consultation for selected products.

    • Medical-benefit and pharmacy products may require information describing the drug use and treatment setting.
    • Part D coverage is denied when Part A or Part B covers the medication as prescribed and dispensed or administered.
    • Haegarda must be prescribed by or in consultation with an immunologist, allergist, or rheumatologist.
    • Hetlioz must be prescribed by or in consultation with a sleep disorder specialist, neurologist, or psychiatrist.
    • Growth hormone must be prescribed by or in consultation with an endocrinologist, nephrologist, infectious disease specialist, gastroenterologist or nutritional support specialist, or geneticist.

    Biosimilar and Reference Product Rules

    Billing Rule

    Document biosimilar-specific coverage requirements

    For Trazimera biosimilar substitutions, coverage requires an intolerable adverse event to Trazimera that was not attributed to the active ingredient as described in the prescribing information. Remicade and Renflexis have separate indication-specific criteria; when the Renflexis adverse-event pathway is used, document an intolerable adverse event to Renflexis not attributed to the active ingredient.

    • Ogivri and Ontruzant: document the required intolerable Trazimera adverse event and the applicable disease-specific criteria.
    • Renflexis and Remicade: document the applicable disease severity, prior therapy, intolerance, contraindication, and combination requirements.
    • For Renflexis, document the prior intolerable adverse event when that criterion is invoked.

    Policy Terms and Abbreviations

    Definitions and abbreviations
    PAH and CTEPHPAH is pulmonary arterial hypertension classified as WHO Group 1. CTEPH is chronic thromboembolic pulmonary hypertension classified as WHO Group 4.
    APR/IPRAPR means adequate platelet response, greater than 50,000/mcL; IPR means inadequate platelet response, less than 50,000/mcL.
    Oncology biomarkers and diseasesRET means rearranged during transfection; GIST means gastrointestinal stromal tumor; HER2 means human epidermal growth factor receptor 2; KRAS G12C-positive means Kirsten rat sarcoma viral oncogene homolog G12C mutation-positive disease; BRCA means breast cancer susceptibility gene mutation.
    High-risk medication terminologyA high-risk medication is potentially inappropriate in older adults and may require avoidance, dose reduction, caution, or close monitoring; a non-HRM alternative is a medication not classified as high risk and used before authorization of the requested HRM.
    Treatment terminologySubsequent therapy is treatment given after prior therapy, generally following progression, inadequate response, or intolerance. TKI means tyrosine kinase inhibitor. BTK inhibitor means Bruton tyrosine kinase inhibitor; examples include acalabrutinib and zanubrutinib.
    Transplant and hematology termsBMT/HSCT means bone marrow transplant or hematopoietic stem cell transplant; an allogeneic HSCT uses donor cells; Ph+ ALL is Philadelphia chromosome-positive acute lymphoblastic leukemia; MDS means myelodysplastic syndrome.
    Respiratory, neurologic, and inflammatory termsAD means atopic dermatitis; LABA means long-acting beta2-agonist; LAMA means long-acting muscarinic antagonist; NSCLC means non-small cell lung cancer; CFTR means cystic fibrosis transmembrane conductance regulator; TNF inhibitor means tumor necrosis factor inhibitor.

    Policy Scope and Background

    This policy is a drug-level prior authorization compendium for prescription, specialty, infusion, biologic, oncology, and vaccine products. It spans oncology and biomarker-directed therapies, hematology, immunology and inflammatory disease, pulmonary hypertension and other pulmonary conditions, neurology and sleep disorders, dermatology, infectious disease, metabolic and enzyme-replacement therapies, and specialty pharmacy products.

    Coverage generally depends on the requested product being used for an FDA-approved or specified medically accepted indication and meeting the applicable clinical requirements. Depending on the drug, the request may require diagnostic confirmation, disease stage or severity, biomarker or mutation results, laboratory thresholds, prior treatment history, required combination therapy, age or prescriber restrictions, and evidence of response for continuation therapy.

    Cross-Drug Criteria Summary

    Criteria Cross-Reference and Decision Logic

    The criteria are organized by product and indication. Each product-level pathway retains its stated ALL, ANY, and alternative-treatment logic; initial therapy and continuation/reauthorization are evaluated separately.

    Drug-specific structure: For each requested product, evaluate the applicable indication, diagnosis confirmation, biomarker or mutation, disease stage or severity, age, laboratory threshold, prescriber or specialist requirement, route, combination regimen, exclusion, prerequisite therapy, and authorization duration.
    Indication-specific pathways: A product may qualify through one of several indication pathways, such as oncology biomarker pathways, inflammatory-disease severity pathways, infection or transplant pathways, neurologic diagnostic pathways, or hematology laboratory pathways.
    Nested prerequisite logic: Where a pathway requires sequential therapy, all required steps must be satisfied in order. Examples include generic anticonvulsant followed by specified branded anticonvulsants; generic followed by brand antipsychotic; topical or systemic therapy before biologic treatment; prior TKI, BTK inhibitor, kinase inhibitor, TNF inhibitor, opioid, triptan, or gabapentin therapy; and required combination partners.
    Initial therapy cross-reference: Initial requests require the applicable product-level diagnosis and severity criteria, diagnostic or biomarker confirmation, baseline laboratory values, age restrictions, prerequisite treatment or contraindication, combination therapy, and route or site-of-care requirements.
    Continuation cross-reference: Renewals require documented clinical benefit, objective response, maintained laboratory response, reduced symptoms or events, improved function, reduced support requirements, wound reassessment, or the required duration and response to prior therapy, as applicable to the product.
    Safety and coordination rules: Do not approve prohibited duplicate therapies or contraindicated combinations, including duplicate CFTR potentiators, duplicate CGRP antagonists, potent CYP3A4 inhibitors with DHE nasal or ergotamine, ketoconazole contraindications, and Part D requests when Part A or Part B coverage applies. Apply product-specific age, specialist, high-risk-medication, anticholinergic/CNS-polypharmacy, and biosimilar-substitution requirements.

    Required Prior Therapy

    Requested product or indicationRequired prerequisite or sequenceFailure, intolerance, contraindication, or exception
    Acitretin — psoriasisMethotrexate or cyclosporine before acitretinInadequate response, intolerance, or contraindication
    Arcalyst — gout-flare preventionMaximum tolerated NSAID and colchicine; concurrent urate-lowering therapyInadequate response, intolerance, or contraindication to NSAID and colchicine
    Bimzelx — ankylosing spondylitis or non-radiographic axial spondyloarthritisNSAID trial before BimzelxInadequate response or intolerance; NSAID contraindication permits exception
    Bosentan — adult new startAmbrisentan before bosentanInadequate response, intolerance, or contraindication to ambrisentan
    Briviact — partial-onset seizuresGeneric anticonvulsant, followed by Aptiom, Xcopri, or Spritam when age-appropriateInadequate response, intolerance, or contraindication to each applicable prerequisite
    Bysanti — schizophrenia or bipolar I mania/mixed episodesOne listed generic antipsychotic, followed by one qualifying brand antipsychoticInadequate response, intolerance, or contraindication to both categories
    Calcipotriene-containing therapy — psoriasisTopical steroid before calcipotrieneInadequate response, intolerance, or contraindication to topical steroid
    Clomipramine — OCD, panic disorder, or depressionSSRI or SNRI; depression requires two alternatives, including SSRIs, SNRIs, mirtazapine, or bupropionInadequate response, intolerance, or contraindication
    Clorazepate or diazepam — applicable indicationsSSRI or SNRI concurrently until effective, or trial of at least two SSRIs/SNRIsInadequate response, intolerance, or contraindication; concurrent use may be used during initiation
    Cresemba — invasive aspergillosis or HIV-associated fluconazole-refractory esophageal candidiasisVoriconazole before CresembaInadequate response, intolerance, or contraindication to voriconazole
    Pyrimethamine — selected prophylaxis or cystoisosporiasis treatmentTMP-SMX before pyrimethamineIntolerance or contraindication to TMP-SMX; immunocompromised status applies to specified prophylaxis
    DHE nasal — migraineAt least one triptan 5-HT1 receptor agonist before DHE nasalInadequate response, intolerance, or contraindication to triptan
    Drizalma — selected anxiety, neuropathic pain, fibromyalgia, or musculoskeletal painDuloxetine capsules before DrizalmaTried duloxetine or unable to take capsules
    Dupixent — atopic dermatitisTopical corticosteroid or topical calcineurin inhibitor before DupixentInadequate response or topical therapy not advisable
    Eprontia — epilepsy or migraine preventionGeneric anticonvulsant; when applicable, Aptiom, Xcopri, or Spritam; immediate-release topiramate for specified indicationsInadequate response, intolerance, or contraindication; swallowing difficulty may qualify for some indications
    Ergotamine — migraineAt least one triptan 5-HT1 agonist before ergotamineInadequate response, intolerance, or contraindication to triptan
    Etanercept — rheumatoid arthritis or axial spondyloarthritisMethotrexate or prior biologic/targeted synthetic DMARD for rheumatoid arthritis; NSAID for axial spondyloarthritisInadequate response, intolerance, or contraindication as applicable
    Fanapt — schizophrenia or bipolar I disorderOne specified generic antipsychotic followed by one specified brand antipsychoticInadequate response, intolerance, or contraindication to both steps
    Fetzima — major depressive disorderTwo alternatives from SNRIs, SSRIs, mirtazapine, or bupropionInadequate response, intolerance, or contraindication to two alternatives
    Fycompa — seizuresGeneric anticonvulsant followed by specified branded anticonvulsants based on seizure typeInadequate response, intolerance, or contraindication to required agents
    Gilotrif — EGFR-positive NSCLCErlotinib, gefitinib, or osimertinib before GilotrifIntolerable adverse event or contraindication; metastatic squamous NSCLC requires progression after platinum chemotherapy
    Amitriptyline — depressionTwo alternative antidepressants: SSRIs, SNRIs, bupropion, mirtazapine, or trazodoneInadequate response or intolerance to two alternatives
    Amitriptyline — extrapyramidal symptomsAmantadine before amitriptylineInadequate response or intolerance; contraindication to amantadine may qualify
    Amitriptyline — Parkinson diseaseTwo of amantadine, carbidopa/levodopa, pramipexole, or ropiniroleInadequate response or intolerance to two alternatives
    Cyproheptadine — rhinitisTwo of levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasalInadequate response or intolerance to two alternatives
    Amitriptyline — anxietyTwo of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-releaseInadequate response or intolerance; acute anxiety may qualify without two trials
    Amitriptyline — insomniaDoxepin 3 mg or 6 mg or ramelteon before amitriptylineInadequate response, intolerance, or contraindication to alternatives
    Humira — inflammatory disease indicationsMethotrexate, NSAID, corticosteroid, phototherapy, or specified conventional/biologic therapy according to indicationInadequate response, intolerance, or contraindication; severity pathway may apply
    Iclusig — GIST or CMLAt least two FDA-approved therapies for GIST; specified prior kinase-inhibitor history for CMLDisease progression, resistance, or intolerance as applicable
    Imatinib/Imkeldi — CMLDocument prior tyrosine kinase inhibitor treatment historyPrior TKI failure is not permitted except when failure was due to intolerance
    Extended-release opioids — chronic painPrior extended-release opioid for at least 30 days or immediate-release opioid for at least 1 weekPrior exposure is waived for qualifying cancer, sickle-cell, terminal-condition, or palliative-care pain
    Jakafi — polycythemia veraHydroxyurea before Jakafi; also Besremi or high-risk disease as applicableInadequate response, intolerance, or resistance to hydroxyurea; additional failure/intolerance or high-risk disease
    Jakafi — essential thrombocythemiaPrior hydroxyurea, interferon therapy, or anagrelideInadequate or lost response
    Jaypirca — CLL/SLL, mantle cell lymphoma, or marginal zone lymphomaPrior BTK inhibitor; covalent BTK inhibitor for marginal zone lymphomaPrior treatment must be documented
    JIDEYTRO — applicable indicationsPrior BTK inhibitor, such as acalabrutinib or zanubrutinib; covalent BTK inhibitor for marginal zone lymphomaPrerequisite therapy is required
    KINERET — rheumatoid arthritisTwo specified advanced therapies before new-start KINERETInadequate response, intolerance, or contraindication to two products
    KINERET — systemic juvenile idiopathic arthritisTyenne before new-start KINERETInadequate response, intolerance, or contraindication to Tyenne
    Lonsurf — gastric, esophageal, or gastroesophageal junction adenocarcinomaAt least two prior chemotherapy linesPrior treatment requirement applies to these indications
    Lorbrena — ROS1-rearrangement-positive NSCLCCrizotinib, entrectinib, ceritinib, or repotrectinib before LorbrenaDisease progression on specified targeted therapy
    Lynparza — uterine leiomyosarcoma or ovarian-family cancersAt least one prior therapy for uterine leiomyosarcoma; maintenance after chemotherapy response for ovarian-family cancersPrior therapy or response requirement must be met
    Megestrol — cancer-related cachexiaMegestrol 40 mg/mL oral suspension before authorizationInadequate response or intolerance
    Mepron — selected PCP or toxoplasmosis indicationsSulfamethoxazole/trimethoprim before MepronIntolerance or contraindication; immunocompromised status required for specified prophylaxis
    Nexavar — GISTAt least two FDA-approved therapies before NexavarDisease progression after prior therapies
    Nurtec — acute migraineAt least one triptan 5-HT1 receptor agonist before NurtecInadequate response, intolerance, or contraindication
    Opipza — schizophrenia or major depressive disorderDiagnosis-specific generic and brand antipsychotic trialsInadequate response, intolerance, or contraindication; inability to swallow oral formulations may qualify
    Pimecrolimus — atopic dermatitis outside sensitive areasAt least one first-line therapy, such as a medium- or higher-potency topical corticosteroidInadequate response, intolerance, or contraindication
    Pregabalin/Lyrica — postherpetic neuralgia or diabetic peripheral neuropathyGeneric gabapentin before pregabalinInadequate response, intolerance, or contraindication; swallowing difficulty applies to oral solution
    Pyzchiva — moderate-to-severe plaque psoriasisPhototherapy, methotrexate, cyclosporine, or acitretin for disease involving at least 3% BSAInadequate response or intolerance; contraindication may qualify
    Qinlock — GISTAt least three kinase inhibitors including imatinib, or specified alternative prior-therapy pathwaysProgression after avapritinib and dasatinib, or imatinib with intolerance to sunitinib, as applicable
    Quetiapine XR — schizophrenia, bipolar disorder, or adjunctive MDDSpecified generic antipsychotic or immediate-release quetiapine before extended-release formulationInadequate response, intolerance, or contraindication
    Relistor injection — opioid-induced constipationOral agent such as Movantik before injectionInadequate response, intolerance, or contraindication; inability to tolerate oral medication may qualify
    Rinvoq — inflammatory diseasesTNF inhibitor before Rinvoq; systemic therapy may substitute for ulcerative colitis/Crohn disease when TNF therapy is clinically inadvisableInadequate response, intolerance, or contraindication; atopic dermatitis requires prior systemic therapy or clinical inadvisability

    Diagnostic and Laboratory Threshold Reference

    Reference values used in coverage criteria
    Pulmonary hypertensionMean pulmonary arterial pressure >20 mmHg; pulmonary capillary wedge pressure ≤15 mmHg; pulmonary vascular resistance >2 Wood units
    Alpha1-proteinase inhibitor replacementPretreatment serum alpha1-proteinase inhibitor <11 micromol/L, equivalent to 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry
    Platelet and eosinophil valuesITP initial platelet count <30,000/mcL, or 30,000-50,000/mcL with symptomatic bleeding or bleeding risk; Dupixent asthma eosinophils ≥150 cells/microliter; Dupixent COPD eosinophils at least 300 cells/microliter; Fasenra HES eosinophils at least 1000 cells/microliter
    Psoriasis severityAt least 10% BSA for biologic first-line therapy; at least 3% BSA with qualifying prior therapy failure, intolerance, or contraindication
    Growth hormone deficiencyPeak GH below 10 ng/mL on 2 failed stimulation tests; height more than 2 standard deviations below mean; SGA birth weight less than 2500 g at gestational age greater than 37 weeks; no catch-up growth by age 2
    Immunoglobulin replacementSerum IgG less than 500 mg/dL for B-cell CLL; less than 400 mg/dL for BMT/HSCT or pediatric HIV; BMT/HSCT requests may also qualify within the first 100 days post-transplant
    Orthostatic hypotension, insulin pump, anemia, and fibrosisnOH: systolic blood pressure decrease ≥20 mmHg or diastolic decrease ≥10 mmHg within 3 minutes of standing or head-up tilt; Omnipod: glucose testing at least 4 times daily or CGM; Procrit: TSAT ≥20%, pretreatment hemoglobin <10 g/dL, MDS erythropoietin ≤500 IU/L, reauthorization hemoglobin <12 g/dL; Rezdiffra: F2-F3 fibrosis
    Policy Summary
    PayerCommonwealth Care Alliance
    PolicyPharmacy Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the requested indication and drug-specific clinical documentation for prior authorization.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaAuthorization Durations and Quantity LimitsClinical Thresholds and Coding ValuesPrior Authorization and Documentation RequirementsSite of Care and Prescriber RequirementsBiosimilar and Reference Product RulesPolicy Terms and AbbreviationsPolicy Scope and BackgroundCross-Drug Criteria SummaryRequired Prior TherapyDiagnostic and Laboratory Threshold Reference
  1. For AD, asthma, EoE, COPD, BP, AFRS, PN, and CSU continuation, the patient must have achieved or maintained clinical benefit. Age limits vary by indication from 6 months for AD to 18 years for COPD, BP, and PN.
  2. Amitriptyline for insomnia requires contraindication to doxepin 3 or 6 mg and ramelteon, or failure or intolerance of one; the prescriber must acknowledge risk and address CNS polypharmacy.
    Octreotide for acromegaly requires elevated pretreatment IGF-1 and inadequate or partial response to surgery/radiotherapy or a clinical reason those treatments were not performed; continuation requires decreased or normalized IGF-1.
  3. Ofev for idiopathic pulmonary fibrosis requires exclusion of other causes and UIP or multidisciplinary-supported diagnosis; progressive fibrosing ILD requires confirmed progression, and systemic-sclerosis ILD requires HRCT confirmation.
  4. Rydapt for AML requires FLT3 mutation-positive disease; FGFR1 or FLT3 rearranged neoplasms must be in chronic or blast phase.
  5. Biomarker confirmation: ALK, BRAF, EGFR, FGFR2, HER2/ERBB2, KRAS G12C, RET, NTRK, BRCA, IDH2, FLT3, FGFR1, KIT, PIK3CA, PDGFRA, PDGFRB, or other product-specific alteration.
  6. Laboratory confirmation: platelet count, hemoglobin, ferritin, IGF-1, eosinophil count, pulmonary hemodynamics, HCV RNA, cystine, enzyme activity, or disease-specific autoantibodies.
  7. Clinical or imaging confirmation: biopsy, HRCT, MRI, CT, polysomnography, sleep-lab evaluation, bone-age assessment, wound assessment, or documented disease manifestations.
  8. Age and specialist restrictions

    • Age restrictions include Benlysta age 5 years or older, Dupixent indication-specific minimum ages, Eucrisa age 3 months or older, Increlex age 2 years or older, Icatibant age 18 years or older, Posaconazole age 2 years or older, and Pyzchiva and oncology products subject to their listed indication requirements.
    • Specialist involvement is required for products such as Berinert, Icatibant, Increlex, Northera when specified, and other disease-specific therapies when the policy requires immunology, allergy, rheumatology, endocrinology, oncology, pulmonology, gastroenterology, hepatology, neurology, or transplant consultation.
  9. Procrit reauthorization requires at least 12 weeks of erythropoietin therapy, response, current hemoglobin below 12 g/dL, and adequate iron stores when required.
  10. Pomalyst, Rubraca, Rydapt, oncology products, and biologics require ongoing disease-specific benefit and continued adherence to the approved regimen and sequencing requirements.
  11. Clorazepate: For anxiety, require concurrent SSRI/SNRI therapy until effective or inadequate response, intolerance, or contraindication to at least two SSRIs/SNRIs. For patients 65 or older, apply the specified short-term, anxiety, or plan-year duration and document the older-adult risk review.
  12. Emsam and other prerequisite-therapy requests: Document required alternative antidepressant trials or contraindications before approval. Fetzima requires inadequate response, intolerance, or contraindication to two alternatives; Fanapt requires antipsychotic step therapy; and quetiapine XR requires generic alternatives and review of concurrent CNS medications.
  13. Ensacove and oncology biomarker criteria: For ALK-positive NSCLC, document recurrent, advanced, metastatic, or qualifying adjuvant disease and ALK positivity. Similar oncology requests require the applicable biomarker, stage, regimen, and prior-treatment documentation; insufficient biomarker or prior-therapy evidence, or a missing oncology regimen, supports denial.
  14. Eprontia, Ergotamine, and migraine therapy: Document required step therapy and alternatives. Ergotamine or dihydroergotamine requires prior triptan therapy and is denied with potent CYP3A4 inhibitors; migraine preventive products must not be combined with another CGRP antagonist.
  15. Erivedge and Erleada: Document the qualifying oncology diagnosis, disease status, biomarker or androgen-receptor indication, and required androgen-deprivation therapy where applicable. Missing androgen-deprivation therapy is a denial risk.
  16. Etanercept, Eucrisa, and topical therapy: Document required prerequisite therapy, including appropriate conventional or topical treatment trials, inadequate response, intolerance, or contraindication.
  17. Exxua and Fanapt: Document the qualifying diagnosis and required antipsychotic or antidepressant alternatives. Fanapt requires prior antipsychotic step therapy unless an alternative is contraindicated or not clinically appropriate.
  18. Fentanyl patch and extended-release opioids: Require a qualifying indication such as cancer, sickle-cell disease, terminal illness, palliative care, or severe persistent pain requiring extended opioid therapy. Document prior opioid exposure, safe dosing, opioid-use-disorder evaluation and monitoring, and either at least 30 days of prior extended-release opioid therapy or at least 1 week of immediate-release opioid therapy. Immediate-release therapy is required before extended-release therapy when specified.
  19. Fycompa: For partial-onset seizures, require inadequate response, intolerance, or contraindication to a generic anticonvulsant and to Aptiom, Xcopri, or Spritam. For primary generalized tonic-clonic seizures, require a generic anticonvulsant and Spritam alternative review.
  20. HER2-directed therapy: Document HER2-positive or HER2-amplified disease, applicable RAS/BRAF status, indication, combination regimen, and prior HER2-inhibitor history. Trastuzumab biosimilar substitution, including KANJINTI and related products, requires an intolerable adverse event to Trazimera not attributed to the active ingredient; Part D denial applies when Part A/B covers administration.
  21. High-risk medication authorization: Apply age and cumulative-duration limits, required alternative therapy, prescriber acknowledgment, and medication-burden review. Deny or pend when high-risk criteria are not met, the patient is below the applicable age threshold, or the duration exceeds the permitted limit without justification.
  22. Insulin pumps and supplies: For pump eligibility, document insulin-requiring diabetes, glucose self-testing, counseling or continuous glucose monitoring, and inadequate control or difficulty with multiple bolus injections. Insulin supplies require documentation that the product is used with insulin.
  23. CFTR potentiator restrictions: Alyftrek and Kalydeco may not be used with another CFTR potentiator, including ivacaftor or deutivacaftor. Avoid duplicate CFTR potentiator therapy; concurrent use is a denial condition.
  24. Mavyret: Exclude moderate or severe hepatic impairment or decompensated cirrhosis (Child-Pugh B or C). Document HCV RNA, genotype, treatment history, cirrhosis status, HIV status, resistance substitutions when applicable, transplant status, and the planned AASLD-IDSA-consistent regimen.
  25. Mepron: For PCP treatment, require intolerance or contraindication to sulfamethoxazole/trimethoprim. For PCP or primary toxoplasmosis prophylaxis, also document immunocompromised status; for babesiosis, document concurrent azithromycin.
  26. Koselugo, central precocious puberty, and age limits: Koselugo for neurofibromatosis type 1 requires age 1 year or older. Central precocious puberty requires qualifying GnRH/LH testing, bone-age assessment, and onset before age 8 in females or 9 in males; coverage is limited to females under 12 and males under 13. Memantine PA applies only to patients younger than 30.
  27. Lapatinib: Document HER2-positive breast cancer and combination with an aromatase inhibitor, capecitabine, or trastuzumab. For colorectal cancer, document HER2 amplification, RAS/BRAF wild-type status, combination with trastuzumab, and no prior HER2 inhibitor.
  28. Posaconazole prophylaxis: Document oral use, prophylaxis indication, weight greater than 40 kg, and age 2 years or older; insufficient prophylaxis documentation is a denial risk.
  29. Pregabalin: For oral solution, document difficulty swallowing solid dosage forms. For diabetic neuropathy or postherpetic neuralgia, document inadequate response, intolerance, or contraindication to generic gabapentin; the HRM restriction applies to patients 65 or older.
  30. CMV prophylaxis: Prevymis requires the applicable CMV serostatus and transplant criteria, transplant type, age, and duration documentation.
  31. Quetiapine XR: Document the qualifying indication, prerequisite generic alternatives or antipsychotic step therapy, and justification for concurrent CNS medications. Unjustified interacting or duplicate CNS therapy is a denial risk.
  32. Infliximab and biosimilars: Document the inflammatory disease diagnosis, prior conventional or biologic therapy, response or intolerance, and applicable biosimilar substitution or benefit criteria.
  33. Rinvoq: Document treatment history, including inadequate response or intolerance to a TNF inhibitor or other required systemic therapy, as applicable to the indication.
  34. Rubraca and oncology prerequisites: Document disease, biomarker, stage, prior treatment, and the required oncology regimen. Missing disease or biomarker evidence supports denial.
  35. Other denial risks: Requests may be denied for growth-hormone exclusion criteria, HES exclusion criteria, unconfirmed pulmonary hypertension or missing hemodynamics, absent platelet count or response, absent autoimmune or hereditary-disease confirmation, absent diagnostic or safety documentation, prohibited CYP3A4 inhibitor combinations, older-adult restrictions, incorrect combination or route, product or patient exclusions, program or indication exclusions, insufficient psoriasis severity or prior therapy, absent NTRK resistance mutation, absent ESR1-mutated breast-cancer evidence, absent fibrosis or response documentation, or specialty-drug medical criteria not being met.
  36. Required documentation: Include clinical and diagnostic records, laboratory and biomarker results, baseline and response measures, prior therapy and alternatives, safety and duration rationale, concomitant-medication justification, disease-specific evidence, specialty-drug medical-necessity documentation, IVIG and hematology records, Fulphila chemotherapy timing, growth-hormone records, hereditary angioedema testing, Increlex baseline height/IGF-1/GH testing, Imkeldi and Inbrija clinical documentation, KALYDECO combination-use documentation, KANJINTI indication and benefit documentation, ketoconazole medical-necessity documentation, Lytgobi FGFR2 documentation, Methylphenidate indication documentation, Modafinil sleep-disorder documentation, Northera response documentation, Nuedexta/Nuplazid documentation, Procrit laboratory documentation, Rezdiffra fibrosis and response documentation, and Rucaparib disease and biomarker documentation.